ESR1 and breast carcinoma: Although ER+ breast cancer patients usually show good initial clinical response to hormone therapy, resistance to such treatment is frequently reported and the molecular mechanism underlying the induction of hormone therapy resistance in ER+ breast cancer is still incompletely understood (Holm et al., 2006).